Live news related to ABIVAX stock (FR0012333284): press releases, earnings publications, share price moves, analyst notes and corporate events. This page is auto-updated whenever new financial information is available.
The latest financial news on ABIVAX mainly cover share price moves et analyst notes. The stock trades at €78,25 on Euronext Paris, down 3,51% at the last update. This page lists the articles published on ABIVAX stock to track the share price, company announcements and any item likely to influence market perception.
The Parisian biotech company specializing in inflammatory diseases is turning red mid-morning, in an SBF 120 itself in sharp decline. This pullback er…
The Parisian biotech company specialized in inflammatory diseases is recovering in a declining Paris market. This rebound comes after several weeks of…
The Parisian biotech company specializing in inflammatory diseases is sinking further into red, in a slightly upward-oriented Paris market. The declin…
The Parisian biotech company specializing in inflammatory diseases is recovering ground mid-morning, following several weeks of selling pressure. The …
The Parisian biotech company specializing in inflammatory diseases continues its decline at midday, in a down-trending market. The stock remains far f…
The Parisian biotech company specializing in inflammatory diseases continues its decline in a downward-trending market. The stock finds itself far fro…
The biotech company specializing in immunology of inflammatory diseases fell back into negative territory on Thursday, erasing part of the rebound fro…
The Paris-based biotechnology company, specializing in chronic inflammatory diseases, announced the selection of seven scientific abstracts dedicated …
The Paris-based biotech specialist in inflammatory diseases is regaining ground this Wednesday, posting a second rebound after several weeks of heavy …
The biotech specializing in inflammatory diseases posts a marked recovery this Tuesday, reversing its trajectory of recent weeks. The rebound occurs a…
